Sarah S. Jackson, Ph.D.

Stadtman Investigator

Infections and Immunoepidemiology Branch


9609 Medical Center Dr.
Room SG/6E212
Rockville, MD 20892

+1 240 276 7814

Research Topics

Dr. Jackson earned an M.P.H. in epidemiology in 2008 from the George Washington University, Washington, DC, and a Ph.D. in epidemiology in 2018 from the University of Maryland, Baltimore. She joined DCEG as a postdoctoral fellow in 2018 and in 2021, she was inducted into the NIH Independent Research Scholar Program and promoted to research fellow. She was selected as an Earl Stadtman tenure-track investigator in the Infections and Immunoepidemiology Branch (IIB) and an NIH Distinguished Scholar in 2023.

Dr. Jackson has received numerous awards for her work, including the Sallie Rosen Kaplan Fellowship for Women Scientists in Cancer Research, NIH Fellows Award for Research Excellence, the NCI Director’s Intramural Innovation Award, William G. Coleman Jr. Ph.D., Minority Health and Health Disparities Research Innovation Award, and the DCEG Intramural Research Award.


Dr. Sarah Jackson’s research seeks to understand how the mechanisms by which differences in both sex and gender identity impact cancer risk and outcomes. Specifically, her research addresses two important questions: 1) How do cancer risk factors, incidence, and outcomes among transgender and gender diverse adults differ from cisgender adults, and 2) How do sex differences (hormones, chromosomes, etc.) influence cancer risk and survival?

Cancer Among Transgender and Gender Diverse Individuals

Worldwide approximately 1% of adults identify as transgender or gender-diverse (TGD), individuals whose gender identity differs from their sex assigned at birth. Cancer is an understudied disease in the TGD population due to the paucity of available data, as gender identity is not collected in most countries’ census, cancer registries, or population-based cohort studies. Due to social stigma and marginalization, TGD persons may be at higher risk of and have increased mortality due to certain cancers compared to cisgender persons related to an increased prevalence of infections like HIV and human papillomavirus (HPV). TGD persons may also be at higher risk of cancers related to obesity, alcohol use, and smoking. Discrimination in healthcare settings may also prevent TGD persons from obtaining preventative services, such as cancer screening, leading to increased cancer disparities in this population.

Dr. Jackson is leading a population-based cohort study of TGD persons in the United Kingdom using primary care data to describe mortality, cancer screening, cancer risk factors, and cancer incidence in the population. She is also leading a pilot study examining the feasibility and acceptability of using self-collected samples for HPV testing in the clinic and at home among TGD people in England. This study will provide important data on prevalence of HPV in trans men and trans women and lead to future studies the utility of using self-collected samples to reach this under screened population.

Sexual Orientation and Gender Identity Data Collection

The lack of sexual orientation and gender identity (SOGI) data collection in the U.S. hinders much of the research into lesbian, gay, bisexual, transgender, and queer (LGBTQ) populations. Dr. Jackson initiated a Sexual and Gender Minority (SGM) Interest Group within the NCI Cohort Consortium to develop and test SOGI measures to advocate for the inclusion of SOGI in existing cohorts and to assist consortium investigators with the development of these measures.

Sex Differences in Cancer Incidence and Survival

Sex and gender differences are especially stark in cancer incidence and survival where men have at least a 2–3 times higher risk than women of developing and dying from most non-reproductive cancers. Historically, this male predominance has been attributed to increased risk-taking behaviors among men contrasted with the health seeking behaviors of women. However, a growing body of research has found that differences in hormones, chromosomes, and gene expression between males and females affect immune response to infections and cancer. Dr. Jackson’s research seeks to understand the relative contributions of these factors in the sex differences in non-reproductive cancer incidence and survival.

Read Dr. Jackson's comments in the article “Men and Cancer”, appearing in Cancer Today, a publication of the American Association for Cancer Research®.

Selected Publications

  1. Jackson SS, Han X, Mao Z, Nogueira L, Suneja G, Jemal A, Shiels MS. Cancer Stage, Treatment, and Survival Among Transgender Patients in the United States. J Natl Cancer Inst. 2021;113(9):1221-1227.
  2. Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, de González AB, Buring JE, Fraser GE, Freedman ND, Gapstur SM, Gierach G, Giles GG, Grodstein F, Hartge P, Jenab M, Kirsh V, Knutsen SF, Lan Q, Larsson SC, Lee IM, Lee MH, Liao LM, Milne RL, Monroe KR, Neuhouser ML, O'Brien KM, Petrick JL, Purdue MP, Rohan TE, Sandin S, Sandler DP, Sawada N, Shadyab AH, Simon TG, Sinha R, Stolzenberg-Solomon R, Tsugane S, Weiderpass E, Wolk A, Yang HI, Zheng W, McGlynn KA, Campbell PT, Koshiol J. Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. J Hepatol. 2020;73(4):863-872.
  3. Jackson SS, Pfeiffer RM, Liu Z, Anderson LA, Tsai HT, Gadalla SM, Koshiol J. Association Between Aspirin Use and Biliary Tract Cancer Survival. JAMA Oncol. 2019;5(12):1802-1804.
  4. Jackson SS, Van De Wyngard V, Pfeiffer RM, Cook P, Hildesheim A, Pinto LA, Jackson SH, Choi K, Verdugo RA, Cuevas M, Yáñez C, Tobar-Calfucoy E, Retamales-Ortega R, Araya JC, Ferreccio C, Koshiol J. Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancer. Sci Rep. 2021;11(1):3686.
  5. Jackson SS, Pfeiffer RM, Gabbi C, Anderson L, Gadalla SM, Koshiol J. Menopausal hormone therapy and risk of biliary tract cancers. Hepatology. 2022;75(2):309-321.

Related Scientific Focus Areas

This page was last updated on Thursday, April 4, 2024